GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (AMEX:PLX) » Definitions » Predictability Rank

Protalix BioTherapeutics (Protalix BioTherapeutics) Predictability Rank


View and export this data going back to 2007. Start your Free Trial

What is Protalix BioTherapeutics Predictability Rank?

1 (5)

Warren Buffett said many times that the companies he likes are:

1. Simple businesses that he understands
2. that have predictable and proven earnings and
3. with economic moat
4. those can be bought at a reasonable price.

It is hard to quantify "simple businesses that he (Buffett) understands", so we will focus on the other three characteristics instead. In GuruFocus Research: What worked in the market from 1998-2008? Part I: Introduction of Predictability Rank, we will show that the businesses that have predictable and proven earnings are usually also simple businesses that an average person could understand.

GuruFocus conducted a back test study of Warren Buffett's strategy of "buying good companies at fair prices" for the years from 1998-2008.


Protalix BioTherapeutics Predictability Rank Calculation

In our database there are 2403 stocks that have been traded from Jan. 2, 1998 to Aug. 31, 2008. We have the complete 10-year financial data and trading prices of these companies for this period. We rank the predictability of these companies based on the consistency of their revenue per share and EBITDA (earning before interest, tax, depreciation and amortization) per share over the past ten fiscal years, and study the correlation between the stock performances and the predictability of the business.

Our study may be subject to these biases and assumptions:

Dividend yields are not counted for investment returns
Effects of price changes due to spin-offs may not be fully adjusted
Study is subjected to survivorship bias due to de-listing, bankruptcy, LBO, M&A, etc.

The correlation between business predictability and investment returns of a company is showed below.

Correlation Between Business Predictability and Investment Returns

PredictablesNon-PredictableAll stocks
Total Number of stocks57018332403
Total Lost Money61830891
Total Lost More Than 50%18412430
Total Lost More Than 90%48690
Average Gain260.6%100.0%138.1%
Median Gain150.0%13.0%39.0%
Maximum Gain2852.0%11483.0%11483.0%
Maximum Loss-100.0%-100.0%-100.0%
Annualized Average Gain12.7%6.7%8.4%
Annualized Median Gain8.9%1.1%3.1%


















For the 570 predictable companies, we have seen strong correlation between the predictability of businesses and the stock performances over the past 10 years, regardless of the valuation of business at 1998. Accordingly, we have ranked the business predictability from 5-star to 1-star, as shown in this table.

Predictability Rank5-Star4.5-Star4-Star3.5-Star3-Star2.5-Star2-Star1-Star (non-predictable)Average among all
% Out of All 2403 Stocks 3.3% 2.9% 3.7% 3.3% 3.3% 3.7% 3.3% 76.3% 100%
% that are in Loss (10y) 3% 10% 8% 9% 11% 18% 16% 45% 37%
Average Gain (10y) 364.6% 330.9% 278.0% 235.1% 243.5% 227.8% 154.8% 100.0% 138.1%
Median Gain (10y) 238.5% 193.5% 171.0% 159.0% 132.5% 113.5% 87.0% 13.0% 39.0%
Maximum Gainer 2228.0% 2547.0% 2452.0% 2852.0% 2432.0% 1892.0% 1807.0% 11483.0% 11483.0%
Maximum Loser -82.0% -53.0% -67.0% -100.0% -83.0% -100.0% -78.0% -100.0% -100.0%
Annualized Average Gain 15.4% 14.6% 13.2% 12.0% 12.2% 11.7% 9.1% 6.7% 8.4%
Annualized Median Gain 12.1% 10.6% 9.8% 9.3% 8.2% 7.3% 6.0% 1.1% 3.1%
















For detailed information about each predictability rank, please go to GuruFocus Research: What worked in the market from 1998-2008? Part I: Introduction of Predictability Rank

Also read:

Part II: What worked in the market from 1998-2008? Part II: Role of Valuations
Part III: Intrinsic Value, Discounted Cash Flow and Margin of Safety

Protalix BioTherapeutics Predictability Rank Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Predictability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Executives
Dror Bashan director, officer: President and CEO 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100
Eliot Forster director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Aharon Schwartz director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Zvi Shmuel Ben director 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Eyal Rubin officer: Sr. VP and CFO C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601
Yaron Naos officer: Sr. VP, Operations 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100
Yael Hayon officer: Vice President, R&D 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401
Zeev Bronfeld director 6 URI STREET, TEL AVIV L3 64954
Amos Bar-shalev director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
David Granot director 6225 NEIL ROAD, RENO NV 89511
Pol F Boudes director C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Moshe Manor officer: President & CEO C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100